Research > Focus A
Dr. med. Erik Jung
University Hospital Heidelberg, Neurology Clinic
Within the frame of Focus A, patient groups likely to benefit from an alkylating or molecularly targeted intervention will be characterized. In addition, predictive biomarkers will be selected and prioritized, and parallel as well as subsequent treatments will be developed to enhance therapeutic benefit in selected molecularly defined subgroups. Overarching goals of the work packages in Focus A are the discovery of molecular lesions relevant for resistance to alkylating chemotherapy (A04, A05, A06), to treatments other than alkylating agents in glioblastoma and a priori unlikely to respond to alkylating treatment (A02, A03) and the unbiased screening for targets against the network structure (A01).
A01
University Hospital Heidelberg, Neurology Clinic
University Hospital Heidelberg, Neurology Clinic
A02
Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), German Cancer Research Center (DKFZ), Paediatric Glioma Research Group
Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), University Hospital Heidelberg, Department of Pediatric Oncology and Hematology
A03
University Hospital Heidelberg, Department of Neurology/Neurooncology
University Hospital Heidelberg, Department of Neurology/Neurooncology,
A04
University Hospital Heidelberg, Department of Neurology
A05
University Hospital Heidelberg, Institute of Pathology, Department Neuropathology
University Hospital Heidelberg, Institute of Pathology, Department Neuropathology
A06
German Cancer Research Center (DKFZ), Junior Research Group Brain Tumor Therapeutic Targets
University Hospital Heidelberg, Institute of Pathology, Department Neuropathology